Johnson & Johnson Stock Performance
Johnson & Johnson shares traded at $269.19, reflecting a modest intraday decline of 0.38% per SID market data. Over the trailing twelve months, JNJ has delivered a robust 25.82% return, with the three-month gain registering at 16.51% and one-month performance at 0.79%, indicating sustained upward momentum that has recently begun to flatten. The stock trades above both its 50-day moving average of $263.54 and its 200-day moving average of $244.20, confirming a technically constructive posture across multiple timeframes. The 14-day RSI stands at 55.9, positioning the stock in neutral territory without overbought or oversold signals. JNJ's beta of 0.349 underscores its historically low volatility relative to the broader market, consistent with its defensive Healthcare sector classification. Average daily trading volume stands at approximately 8.82 million shares, according to Massive/Polygon data, reflecting deep institutional liquidity. The company's market capitalization currently sits at approximately $505.8 billion.
Johnson & Johnson Valuation Analysis
Johnson & Johnson currently trades at a price-to-earnings ratio of 20.30, positioning it within a moderate valuation range for large-cap Healthcare companies, per SID market data. The PEG ratio of 1.91 suggests the stock is trading near fair value relative to its expected earnings growth trajectory, with a reading above 1.0 indicating the market is pricing in a premium over the company's growth rate. JNJ's price-to-book ratio stands at 6.43, reflecting significant intangible asset value tied to its pharmaceutical and medical device portfolios. The company maintains a dividend yield of approximately 2.45%, according to SEC filings, continuing its long-standing commitment to shareholder returns through consistent dividend payments. At a market capitalization of $505.8 billion, JNJ remains one of the largest Healthcare entities globally. These valuation metrics collectively indicate a stock that commands a premium but remains anchored by steady cash flow generation and diversified revenue streams across its business segments.
Smart Money Activity for JNJ
Johnson & Johnson's composite smart money score registers at 50 out of 100, reflecting a neutral overall signal per SID market data. Institutional ownership sentiment scores a perfect 25 out of 25, indicating strong conviction among major asset managers and fund complexes maintaining or increasing their JNJ positions in recent 13F institutional filings. In contrast, insider activity scores just 4.6 out of 25, driven by a notable imbalance in insider transactions: over the past 90 days, there have been 14 insider trades recorded, comprising 4 purchases and 10 sales, according to SEC Form 4 filings. This sell-heavy pattern warrants monitoring, though insider sales at large-cap companies frequently relate to diversification and compensation-plan exercises rather than bearish sentiment. Dark pool activity scores 9.4 out of 25, suggesting below-average hidden institutional accumulation. Congressional trading activity scores 11.2 out of 25, reflecting moderate legislative interest. The divergence between strong institutional positioning and weak insider buying creates a mixed composite reading for smart money analysis.
Johnson & Johnson Earnings Outlook
Johnson & Johnson has demonstrated consistent earnings execution across recent quarters, per company earnings reports. In the January 2026 quarter, JNJ reported earnings per share of $2.46 against an analyst estimate of $2.47, resulting in a marginal miss of $0.01. The company rebounded in the April 2026 quarter with EPS of $2.70 versus the $2.67 consensus, delivering a $0.03 positive surprise. Most recently, the July 2026 quarter showed further improvement with EPS of $2.90 against estimates of $2.85, representing a $0.05 beat. This sequential acceleration from a slight miss to consecutive beats suggests strengthening operational performance. Looking ahead, analysts project EPS of $2.55 for the October 2026 quarter, according to consensus analyst estimates. The earnings trajectory reflects steady growth across JNJ's pharmaceutical and MedTech segments. The pattern of narrowing and then exceeding expectations over three consecutive quarters indicates improving visibility into the company's near-term profitability outlook.
Wall Street Analyst Ratings for JNJ
Wall Street consensus on Johnson & Johnson remains decidedly bullish, with recent analyst activity uniformly reaffirming positive ratings, per SID consensus data. In September 2026, HSBC reiterated its Buy rating on JNJ, followed by UBS also maintaining its Buy recommendation. Guggenheim reaffirmed its Buy rating in August 2026, while Wells Fargo maintained its Overweight designation during the same period, according to Wall Street analyst reports. Notably, Guggenheim issued an additional Buy reiteration in July 2026 covering the company's REIT-related segment. Across all five most recent analyst actions, none involved a downgrade or initiation at a neutral or negative rating, reflecting uniform confidence in JNJ's fundamental trajectory. The consistency of these reaffirmations—spanning major global banks and boutique research firms—suggests broad institutional agreement on the company's growth drivers, including its pharmaceutical pipeline and MedTech segment performance. The absence of any sell-side dissent across these recent updates represents a notable degree of consensus alignment for a mega-cap Healthcare name.
